Qianhai Health Holdings (HKSE:00911) Beneish M-Score: 0.00 (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00911 Qianhai Health Holdings Ltd HKSE:00911
39 GF Score
Price HK$0.60
GF Value HK$0.22
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Qianhai Health Holdings Beneish M-Score?

Qianhai Health Holdings HKSE:00911 +14.29% 39 Beneish M-Score is 0.00 as of Aug. 18, 2026. GuruFocus rates HKSE:00911 with a GF Score™ of 39/100 and a GF Value™ of HK$0.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 913 Drug Manufacturers companies, Qianhai Health Holdings ranks worse than 109528.92% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Qianhai Health Holdings's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Qianhai Health Holdings was 5.08. The lowest was -8.83. And the median was -1.67.

Qianhai Health Holdings Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Qianhai Health Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qianhai Health Holdings Beneish M-Score Chart

Qianhai Health Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.67 -0.45 0.00 0.00 0.00

Qianhai Health Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:00911 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Qianhai Health Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qianhai Health Holdings Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Qianhai Health Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Qianhai Health Holdings's Beneish M-Score falls into.


HKSE:00911
39GF Score
Qianhai Health Holdings Ltd HKSE:00911
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qianhai Health Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Qianhai Health Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was HK$222.7 Mil.
Revenue was HK$677.1 Mil.
Gross Profit was HK$23.6 Mil.
Total Current Assets was HK$388.7 Mil.
Total Assets was HK$408.4 Mil.
Property, Plant and Equipment(Net PPE) was HK$19.6 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$1.5 Mil.
Selling, General, & Admin. Expense(SGA) was HK$14.0 Mil.
Total Current Liabilities was HK$17.2 Mil.
Long-Term Debt & Capital Lease Obligation was HK$0.0 Mil.
Net Income was HK$5.9 Mil.
Gross Profit was HK$0.0 Mil.
Cash Flow from Operations was HK$38.3 Mil.
 Total Receivables was HK$98.7 Mil.
Revenue was HK$519.7 Mil.
Gross Profit was HK$29.7 Mil.
Total Current Assets was HK$386.2 Mil.
Total Assets was HK$407.3 Mil.
Property, Plant and Equipment(Net PPE) was HK$21.2 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$2.4 Mil.
Selling, General, & Admin. Expense(SGA) was HK$15.5 Mil.
Total Current Liabilities was HK$21.3 Mil.
Long-Term Debt & Capital Lease Obligation was HK$0.4 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(222.67 / 677.121) / (98.746 / 519.699)
=0.328848 / 0.190006
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(29.67 / 519.699) / (23.598 / 677.121)
=0.057091 / 0.03485
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (388.737 + 19.649) / 408.386) / (1 - (386.155 + 21.154) / 407.309)
=0 / 0
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=677.121 / 519.699
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.4 / (2.4 + 21.154)) / (1.519 / (1.519 + 19.649))
=0.101894 / 0.071759
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14.043 / 677.121) / (15.493 / 519.699)
=0.020739 / 0.029811
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 17.186) / 408.386) / ((0.424 + 21.315) / 407.309)
=0.042083 / 0.053372
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(5.941 - 0 - 38.312) / 408.386
=-0.079266

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Qianhai Health Holdings (HKSE:00911) has a Beneish M-Score of 0.00 as of Aug. 18, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Qianhai Health Holdings and its competitors. According to the industry distribution chart, Qianhai Health Holdings ranks #999999 out of 913 companies in the Drug Manufacturers industry.
Is Qianhai Health Holdings' Beneish M-Score too high?
Qianhai Health Holdings' current Beneish M-Score is 0.00. Based on the distribution chart, Qianhai Health Holdings ranks #999999 out of 913 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Qianhai Health Holdings has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qianhai Health Holdings' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Qianhai Health Holdings ranks #999999 out of 913 companies for Beneish M-Score. This places Qianhai Health Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Qianhai Health Holdings and its competitors. Qianhai Health Holdings's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qianhai Health Holdings stock overvalued right now?
Based on GuruFocus' analysis, Qianhai Health Holdings (HKSE:00911) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.22, compared to a current price of HK$0.60 — trading 172.7% above its estimated fair value. The current Beneish M-Score is 0.00. Qianhai Health Holdings' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Qianhai Health Holdings (HKSE:00911), the current Beneish M-Score is 0.00 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qianhai Health Holdings (HKSE:00911) Overvalued in 2026?

Based on GuruFocus' analysis, Qianhai Health Holdings stock appears to be overvalued. The current stock price of HK$0.60 is trading 172.7% above its estimated GF Value™ of HK$0.22. GuruFocus considers Qianhai Health Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:00911:

  • Beneish M-Score: 0.00
  • GF Value™: HK$0.22 vs. price of HK$0.60 (172.7% above fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the HKSE:00911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qianhai Health Holdings Business Description

Address 177-183 Wing Lok Street, Room 301-3, 3rd Floor, Wing Tuck Commercial Centre, Sheung Wan, Hong Kong, HKG
Qianhai Health Holdings Ltd principally engaged in the sale of health products and electronic component products. It includes Chinese herbal medicines, skin-care and other healthcare products, and the sale of information technology components. The operating segments of the group are Healthcare products and Electronic component products. Healthcare products include the sale of healthcare products, including Chinese herbal medicines, skincare, and other healthcare products. Electronic component products include the sale of information technology components products including central processing units and semiconductors. The group's revenue is all derived from Hong Kong.
39GF Score

Get the complete analysis for HKSE:00911

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.60
Price
HK$0.22
GF Value